Q32 Bio Inc.
QTTB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.04 | 0.01 | -0.01 |
| FCF Yield | -13.11% | -64.39% | -62.02% | -27.24% |
| EV / EBITDA | 1.85 | 1.97 | 2.50 | -2.55 |
| Quality | ||||
| ROIC | -14.32% | -14.92% | -17.52% | -18.28% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.57 | 1.12 | 1.13 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 72.84% | 6.24% | -9.20% | 41.62% |
| Safety | ||||
| Net Debt / EBITDA | 5.18 | 3.97 | 4.40 | -8.80 |
| Interest Coverage | 0.00 | -30.57 | -40.76 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -900.00 | 0.00 | 0.00 |